Two recent studies have provided strong evidence that denosumab, a fully humanized monoclonal antibody that binds and inactivates the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for carriers of BRCA1/2 mutations, a group of woman predisposed to high lifetime risks of breast and ovarian cancer [1, 2]. The gene discussed is TNFSF11; the disease is ovarian carcinoma.